FDA Grants Priority Review to BeOne’s BRUKINSA Combination for Mantle Cell Lymphoma

The FDA granted priority review to BeOne Medicines’ BRUKINSA combination for first-line mantle cell lymphoma. The body says the combination would be the first and only chemotherapy-free BTK inhibitor option if approved.